InsiderSignalSign in

← Insider buys

EDIT

Editas Medicine, Inc. · Healthcare

Insiders sold $42K of Editas Medicine, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$42KSold, 12 mo

$368.6MMarket cap

EDIT over the last year

No insider buys filed in this year

EDIT after insider buys

3 months after each buy, from the first price a copier could get.

−23.5%Average

−32.3 ptsVs S&P 500

0 of 3Higher

3 buys since 2016 with 3 months of prices.

Every filing

104 insider filings since 2016, newest first

Gilmore Neil O'Neill · CEO

$42K−5.8%Jun 5

Linda Burkly · EVP and Chief Scientific Officer

$64K−14.0%Jul 26

Baisong Mei · EVP and Chief Medical Officer

$34K−5.0%Jul 22

Gilmore Neil O'Neill · CEO

$67K−4.0%Jun 6

Erick Lucera · EVP and CFO

$125K−16.0%May 22

Jessica Hopfield · Director

$254K+198.0%May 14

Gilmore Neil O'Neill · CEO

$733K−19.0%Mar 5

Baisong Mei · SVP and Chief Medical Officer

$191K−13.0%Mar 5

Baisong Mei · SVP and Chief Medical Officer

$38K−6.0%Jul 21

Gilmore Neil O'Neill · CEO

$62K−5.0%Jun 7

Mark S Shearman · EVP and Chief Scientific Officer

$27K−4.0%Feb 15

Michelle Robertson · EVP and CFO

$41K−5.0%Feb 15

Bruce Eaton · EVP, CBO, CTO

$32K−5.0%Feb 15

Mark S Shearman · EVP and Chief Scientific Officer

$52K−7.0%Jun 16

Bruce Eaton · EVP and Chief Business Officer

$41K−2.0%Apr 4

Michelle Robertson · CFO

$45K−5.0%Jan 13

James C Mullen · CEO

$492K−19.0%Jan 4

Lisa Anne Michaels · EVP and Chief Medical Officer

$60K−8.0%Nov 15

James C Mullen · CEO

$525K−19.0%Oct 20

Michelle Robertson · CFO

$150K−8.0%Aug 10

Michelle Robertson · CFO

$125K−8.0%Jun 30

Jessica Hopfield · Director

$264K+34.0%Mar 5

James C Mullen · CEO

$1.2M+250.0%Mar 4

Cynthia Collins · CEO

$84K−3.0%Feb 10

Michelle Robertson · CFO

$123K−8.0%Jan 13

Charles Albright · EVP and Chief Scientific Officer

$632K−29.0%Dec 17

Charles Albright · EVP and Chief Scientific Officer

$450K−29.0%Dec 11

Charles Albright · EVP and Chief Scientific Officer

$800K−45.0%Dec 8

Charles Albright · EVP and Chief Scientific Officer

$94K−11.0%Oct 16

Cynthia Collins · CEO

$72K−4.0%Aug 21

Charles Albright · EVP and Chief Scientific Officer

$353K−26.0%Aug 19

Charles Albright · EVP and Chief Scientific Officer

$383K−27.0%Aug 10

Charles Albright · EVP and Chief Scientific Officer

$97K−10.0%Jul 17

Charles Albright · Chief Scientific Officer

$147K−21.0%Feb 4

Cynthia Collins · CEO

$134K−31.0%Aug 21

Vickesh Myer · CTO

$74K−100.0%Mar 20

Jessica Hopfield · Director

$244K+152.0%Mar 7

Vickesh Myer · CTO

$61K−100.0%Feb 22

Andrew A. F. Hack · CFO

$147K−100.0%Feb 6

Vickesh Myer · CTO

$185K−100.0%Jan 18

Katrine Bosley · President and CEO

$303K−1.0%Jan 10

Andrew A. F. Hack · CFO

$157K−100.0%Jan 8

Vickesh Myer · CTO

$193K−100.0%Dec 19

Katrine Bosley · President and CEO

$383K−1.0%Dec 6

Andrew A. F. Hack · CFO

$149K−100.0%Nov 27

Vickesh Myer · CTO

$191K−100.0%Nov 21

Katrine Bosley · President and CEO

$323K−1.0%Nov 5

Andrew A. F. Hack · CFO

$154K−100.0%Oct 30

Vickesh Myer · CTO

$204K−100.0%Oct 19

Katrine Bosley · President and CEO

$372K−1.0%Oct 3

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.